home / stock / adag / adag news

ADAG News and Press, Adagene Inc. From 11/29/21

Stock Information
Company Name: Adagene Inc.
Stock Symbol: ADAG
Market: NASDAQ
Website: adagene.com
Menu
ADAG ADAG Quote ADAG Short ADAG News ADAG Articles ADAG Message Board
Get ADAG Alerts

News, Short Squeeze, Breakout and More Instantly...
ADAG - CPIX, ADAG, BLU and LIZI among after hour movers

Gainers: Cumberland Pharmaceuticals (NASDAQ:CPIX) +131%. Adagene (NASDAQ:ADAG) +12%. Chimerix (NASDAQ:CMRX) +11%. PLAYSTUDIOS (NASDAQ:MYPS) +8%. Verastem (NASDAQ:VSTM) +6%. Losers: BELLUS Health (NASDAQ:BLU) -7%. LIZHI (NASDAQ:LIZI) -5%. NRX Pharmaceuticals (NASDAQ:NRXP) -5%. G...
ADAG - Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

SAN DIEGO and SUZHOU, China, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced ...

ADAG - Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021

SAN DIEGO and SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced ...

ADAG - Adagene to Participate in Upcoming Investor & Industry Conferences in November

SAN DIEGO and SUZHOU, China, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced ...
ADAG - Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting

- Presentations demonstrate compelling preclinical differentiation of an anti-CD47 antibody and a CD20xCD3 bispecific T-cell engager, both leveraging SAFEbody ™ technology - - Both candidates designed to overcome development challenges of two promising immuno-oncology t...

ADAG - Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium - - ADG106 now being evaluated in combinations with three leading anti-PD-1...

ADAG - Adagene to Participate in the Jefferies Virtual China Biotech Summit

SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announ...
ADAG - Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, tod...

ADAG - Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

- Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three clinical-stage oncology candidates - - Evidence of ADG106 efficacy with favorable safety profile shown in monotherapy trials; combination trials ramping up ...

ADAG - Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it has en...
Previous 10 Next 10